MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Gilead Sciences Inc.

Închisă

SectorSănătate

111.99 0.86

Rezumat

Modificarea prețului

24h

Curent

Minim

110.44

Maxim

111.99

Indicatori cheie

By Trading Economics

Venit

530M

1.8B

Vânzări

29M

7.6B

P/E

Medie Sector

294.868

63.778

EPS

1.9

Randament dividend

2.82

Marjă de profit

23.557

Angajați

17,600

EBITDA

-655M

3.1B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+3.64% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

2.82%

2.39%

Următoarele câștiguri

24 apr. 2025

Data viitoare de dividende

26 iun. 2025

Următoarea dată ex-dividende

13 iun. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

18B

140B

Deschiderea anterioară

111.13

Închiderea anterioară

111.99

Sentimentul știrilor

By Acuity

46%

54%

169 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Gilead Sciences Inc. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 feb. 2025, 21:17 UTC

Câștiguri

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

19 dec. 2024, 15:25 UTC

Principalele dinamici ale pieței

Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding

19 dec. 2024, 13:38 UTC

Principalele dinamici ale pieței

Assembly Biosciences Gets $30.1 Million Equity Investment, Funding From Gilead

6 nov. 2024, 22:25 UTC

Câștiguri

Gilead Sciences Post Higher 3Q Revenue, Raises Fiscal Year Guidance

19 mar. 2025, 14:50 UTC

Top știri

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28 feb. 2025, 12:00 UTC

Top știri

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 feb. 2025, 22:13 UTC

Market Talk
Câștiguri

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11 feb. 2025, 21:06 UTC

Câștiguri

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences Raises Dividend 2.6%>GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences Sees 2205 Veklury Sales $1.4B>GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences Sees 2025 Sales $28.2B-$28.6B >GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences 4Q >GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences 4Q HCV Products Sales >GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences 4Q Rev Up on HIV, Oncology, Liver Disease; Partially Offset by lower sales of Veklury (Remdesivir) >GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences 4Q Adj EPS $1.90 >GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences 4Q Rev $7.57B >GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences 4Q EPS $1.42 >GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences 4Q EPS $1.42 >GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences 4Q Net $1.78B >GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences 4Q Rev $7.6B >GILD

11 feb. 2025, 21:02 UTC

Câștiguri

Gilead Sciences 4Q Adj EPS $1.90 >GILD

10 ian. 2025, 10:30 UTC

Top știri

Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point. -- WSJ

29 dec. 2024, 08:00 UTC

Achiziții, Fuziuni, Preluări

Gilead Buys $20.1 Million of Assembly Biosciences Stock -- Barrons.com

19 dec. 2024, 13:23 UTC

Principalele dinamici ale pieței

Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead

7 nov. 2024, 16:23 UTC

Câștiguri

Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise -- IBD

Comparație

Modificare preț

Gilead Sciences Inc. Așteptări

Obiectiv de preț

By TipRanks

3.64% sus

Prognoză pe 12 luni

Medie 115.33 USD  3.64%

Maxim 140 USD

Minim 90 USD

În baza a 23 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGilead Sciences Inc. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

23 ratings

17

Cumpărare

6

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

109.84 / 112.2Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Neutral Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

169 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.